Amanote Research
Register
Sign In
Retraction: Modulation of CD59 Expression by Restrictive Silencer Factor-Derived Peptides in Cancer Immunotherapy for Neuroblastoma
Cancer Research
- United States
doi 10.1158/0008-5472.can-13-2936
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
November 7, 2013
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
Retraction: Targeting Neural-Restrictive Silencer Factor Sensitizes Tumor Cells to Antibody-Based Cancer Immunotherapy in Vitro via Multiple Mechanisms
Journal of Immunology
Allergy
Immunology
Sphingolipid Modulation of Angiogenic Factor Expression in Neuroblastoma
Cancer Prevention Research
Medicine
Cancer Research
Oncology
Dysregulation of Platelet-Derived Growth Factor -Receptor Expression by Np73 in Neuroblastoma
Molecular Cancer Research
Cancer Research
Oncology
Molecular Biology
Neuron-Restrictive Silencer Factor–mediated Downregulation of Μ-Opioid Receptor Contributes to the Reduced Morphine Analgesia in Bone Cancer Pain
Pain
Neurology
Anesthesiology
Pain Medicine
Pharmacology
Tissue-Specific Expression of the L1 Cell Adhesion Molecule Is Modulated by the Neural Restrictive Silencer Element
Journal of Cell Biology
Medicine
Cell Biology
Development of Next Generation Antibody-Based Immunotherapy for Childhood Cancer Neuroblastoma
The Lancet
Medicine
Expression of SART3 Antigen and Induction of CTLs by SART3-derived Peptides in Breast Cancer Patients
British Journal of Cancer
Cancer Research
Oncology
Toll-Like Receptor-4 Modulation for Cancer Immunotherapy
Frontiers in Immunology
Allergy
Immunology
Neuroblastoma-Derived Secretory Protein Is a Novel Secreted Factor Overexpressed in Neuroblastoma
Molecular Cancer Therapeutics
Cancer Research
Oncology
